Evidence map›Paper›PMID 38672598›Full record

ArticleCancers2024

Proteomic Analysis of Spatial Heterogeneity Identifies HMGB2 as Putative Biomarker of Tumor Progression in Adult-Type Diffuse Astrocytomas.

Aline P Becker, Valesio Becker, Joseph McElroy, Amy Webb, Chunhua Han, Yingshi Guo, Erica H Bell, Jessica Fleming, Ilinca Popp, Ori Staszewski and 5 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 3 institutions in 2 countries.

Aline P BeckerDepartment of Radiation Oncology, The Ohio State University, Columbus, OH 43210, USA.ORCID 0000-0002-8695-810X
Valesio BeckerDepartment of Radiation Oncology, The Ohio State University, Columbus, OH 43210, USA.
Joseph McElroyCenter for Biostatistics, The Ohio State University, Columbus, OH 43210, USA.
Amy WebbSchool of Biomedical Science-Biomedical Informatics, The Ohio State University, Columbus, OH 43210, USA.
Chunhua HanDepartment of Radiation Oncology, The Ohio State University, Columbus, OH 43210, USA.
Yingshi GuoDepartment of Radiation Oncology, The Ohio State University, Columbus, OH 43210, USA.
Erica H BellDepartment of Neurology, The Ohio State University, Columbus, OH 43210, USA.
Jessica FlemingDepartment of Radiation Oncology, The Ohio State University, Columbus, OH 43210, USA.
Ilinca PoppDepartment of Radiation Oncology, University of Freiburg, 79110 Freiburg, Germany.
Ori StaszewskiInstitute of Neuropathology, Medical Faculty of the Saarland University, 66421 Homburg, Germany.ORCID 0000-0002-0579-6701
Marco PrinzInstitute of Neuropathology, Faculty of Medicine, University of Freiburg, 79106 Freiburg, Germany.
Jose J OteroDepartment of Pathology, The Ohio State University, Columbus, OH 43210, USA.
Saikh Jaharul HaqueDepartment of Radiation Oncology, The Ohio State University, Columbus, OH 43210, USA.
Anca-Ligia GrosuDepartment of Radiation Oncology, University of Freiburg, 79110 Freiburg, Germany.
Arnab ChakravartiDepartment of Radiation Oncology, The Ohio State University, Columbus, OH 43210, USA.ORCID 0000-0002-5392-8721
The Ohio State University · USUniversity of Freiburg · DESaarland University · DE

Funding

OSU as Network Lead Academic Participating Site for the NCI NCTNU10CA180850 · NCI · OHIO STATE UNIVERSITY · PI BLUM, KRISTIE A, CHAKRAVARTI, ARNAB · 2014 to 2018
$6.8M
Signal Transduction Pathways in GlioblastomaR01CA108633 · NCI · OHIO STATE UNIVERSITY · PI CHAKRAVARTI, ARNAB · 2005 to 2009
$2.3M
TOWARDS A REFINED MOLECULAR RECURSIVE PARTITIONING ANALYSIS MODEL FOR GLIOBLASTOMRC2CA148190 · NCI · AMERICAN COLLEGE OF RADIOLOGY · PI ALDAPE, KENNETH D, CHAKRAVARTI, ARNAB · 2009 to 2010
$2.1M
Therapeutic Exploitation of Mutant BRAF for AstrocytomaR01CA169368 · NCI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI HOUGHTON, PETER J · 2013 to 2017
$1.6M
NCI NIH HHS R01CA108633NCI NIH HHS R01CA169368NCI NIH HHS RC2CA148190NCI NIH HHS U10CA180850-676 01
6 · The paper itself

Abstract

Although grading is defined by the highest histological grade observed in a glioma, most high-grade gliomas retain areas with histology reminiscent of their low-grade counterparts. We sought to achieve the following: (i) identify proteins and molecular pathways involved in glioma evolution; and (ii) validate the high mobility group protein B2 (HMGB2) as a key player in tumor progression and as a prognostic/predictive biomarker for diffuse astrocytomas. We performed liquid chromatography tandem mass spectrometry (LC-MS/MS) in multiple areas of adult-type astrocytomas and validated our finding in multiplatform-omics studies and high-throughput IHC analysis. LC-MS/MSdetected proteomic signatures characterizing glioma evolution towards higher grades associated with, but not completely dependent, on IDH status. Spatial heterogeneity of diffuse astrocytomas was associated with dysregulation of specific molecular pathways, and HMGB2 was identified as a putative driver of tumor progression, and an early marker of worse overall survival in grades 2 and 3 diffuse gliomas, at least in part regulated by DNA methylation. In grade 4 astrocytomas, HMGB2 expression was strongly associated with proliferative activity and microvascular proliferation. Grounded in proteomic findings, our results showed that HMGB2 expression assessed by IHC detected early signs of tumor progression in grades 2 and 3 astrocytomas, as well as identified GBMs that had a better response to the standard chemoradiation with temozolomide.

Indexed as

gene methylationglioblastomagliomaHMGB2mass spectrometryproteomic profiletumor heterogeneity

Identifiers

PMID38672598
PMCPMC11049315
OpenAlexW4394836985

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.